

MONTHLY MEDICATION SAFETY UPDATE

Information for health professionals in NSW public health organisations

This is a summary of medication safety and supply related issues affecting NSW public health facilities in **December 2023**. Updates regarding current medication-specific safety and supply related issues are available on the [CEC website](#).

Medication safety issues under investigation

- Disruptions to supply – gliclazide, prochlorperazine and valganciclovir tablets

Relevant clinician information to note

- CEC updates:
 - Consensus Guideline: Remdesivir and nirmatrelvir plus ritonavir in renal impairment – [updated](#)
 - Guide to using the Adult National Inpatient Medication Chart (NIMC) – during eMR downtime – [updated](#)
- TGA updates:
 - Sodium chloride contamination – information available [here](#)
 - Romosozumab (Evenity) – [safety alert](#)
 - Sitagliptin diabetes medicines – [safety advisory](#)
 - Vyvanse (lisdexamfetamine dimesilate) capsules – [shortage](#)
 - Fluoxetine 20 mg dispersible tablets (Zactin Tabs) – [updated shortage information](#) and Serious Scarcity Substitution Instrument available [here](#)
 - Compounded semaglutide-like products – [safety alert](#)
 - Bicillin L-A (benzathine benzylpenicillin tetrahydrate) prefilled syringe for injection – [shortage](#)
 - Liu Wei Di Huang Wan (Rehmannia Six Formula) BP015 – [recall](#)
 - Kin Fertility, Prenatal Capsules – [recall](#)
 - Several products containing undeclared sildenafil and sibutramine – safety advisories available [here](#)

Current projects with eHealthNSW

- The project phase of the NSW Medicines Formulary online platform has now concluded, and processes for the maintenance and optimisation of the platform have commenced. The next release is expected in March 2024, with new features such as a 'Latest Updates' page for a summary of recent formulary submission outcomes and the ability to include hyperlinks within formulary restrictions and notes. The Individual Patient Use Business Case is currently under review, with an outcome expected in the coming weeks.
- Continued collaboration on the VTE Prevention eMR project, which is currently being piloted in WSLHD and NBMLHD sites.

Medication Safety and Supply Summary

| | |
|----|--|
| 29 | SAFETY/SUPPLY ISSUES REQUIRING INVESTIGATION BY THE MEDICATION SAFETY TEAM |
| 12 | WERE REPORTED TO THE FRONTLINE DUE TO SAFETY RISK REQUIRING LOCAL MITIGATION |
| 6 | RESULTED IN FORMAL SAFETY COMMUNICATION |
| 2 | PREVIOUS ISSUES RESOLVED ON CEC ONLINE PORTAL |

Safety Alerts/Notices/Information released

SI:016/23 [Updated: Optimisation of elastomeric infusion devices](#)

– 14 December 2023

SN:040/23 [Updated: Disruption to supply – Benzathine benzylpenicillin \(Bicillin L-A\) suspension for injection pre-filled syringe](#)

– 15 December 2023

SN:041/23 [Updated: Possible contamination of multiple sodium chloride products – Quarantine and recall actions](#)

– 15 December 2023

SN:044/23 [Updated: Safe use of magnesium sulfate heptahydrate in maternity services](#)

– 20 December 2023

Medication Safety Communications released

[Xylocaine® 2% with adrenaline 1:200,000 20 mL injection vial](#)

– 7 December 2023

[Hydroxocobalamin 1 mg/1 mL solution for injection](#)

– 14 December 2023

Medications reported on online portal this month

[Ampicillin, disulfiram, fluoxetine dispersible tablets, Gastrografin, hydroxocobalamin, lisdexamfetamine, tirzepatide, Xylocaine 2% with adrenaline 1:200,000 20 mL injection vial](#)

Contact us

If you need support or assistance with medication safety matters in your facility, please email us: CEC-MedicationSafety@health.nsw.gov.au.